| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President, R& D and Tech Ops | Head of R& D, CSO | Chief Scientific Officer
1 company
Louise Rodino-Klapac is President, R& D and Tech Ops at SRPT. Louise Rodino-Klapac's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.8M at current prices.
Net of sales, the SRPT filings show accumulation of 3,780 shares.
Louise Rodino-Klapac has 29 Form 4 filings on record from December 2020 to September 2026, all as President, R & D and Tech Ops at Sarepta Therapeutics (SRPT), 2020–2026.
The 50 reported transactions were 26 tax withholdings, 11 option or other derivative awards, 8 stock awards and 4 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $300K and no sales.
The only open-market purchase was 3,780 shares of SRPT at an average $79.33 on November 24, 2021, about $300K. Twelve months later SRPT was up 41%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 24, 2021 | SRPT Sarepta Therapeutics, Inc. | Head of R& D, CSO | Buy | 3,780 | $79.33 | $299,867.40 | +6.1% | -7.3% | +41.5% |